慢性C型肝炎感染におけるプライマリインターフェロン耐性および治療反応:パイロット研究
Lancet (London, England)
|October 25, 2001
まとめ
インターフェロン1回投与後の早期のウイルス負荷低下は,慢性C型肝炎ウイルス遺伝子型1 (HCV-1) の患者における治療の成功を予測します. 70%未満の低下は,併用療法への反応がないことを示します.
科学分野:
- 肝臓病理学 肝臓病理学
- ウイルス学 ウイルス学 ウイルス学
- ファルマコダイナミクスは,
背景:
- 慢性C型肝炎ウイルス遺伝子型1 (HCV-1) 感染症は,標準的なインターフェロンおよびリバビリン療法で低持続性ウイルス学的応答率 (30%) を有する.
- 治療反応を予測することは,患者の管理と治療戦略の最適化に不可欠です.
関連する概念動画
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...


